Released
September 19, 2025
Expires
August 28, 2026
Media Type
Internet
Completion Time
60 minutes
Specialties
Cardiology, Hematology/Oncology
Topics
Leukemia, Oncology
Providers
Provided by The France Foundation and the International Cardio-Oncology Society.
Grant Support
This activity is supported in part by an independent education grant from AstraZeneca and Lilly.
Credits Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Nursing Contact Hour
- PAs — 1 AAPA Category 1 CME credit
All other health care professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of hematology/oncology, cardio-oncology, and cardiology clinicians including physicians, nurse practitioners, physician assistants, nurses, and fellows.
Program Overview
Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL), but not without cardiovascular trade-offs. Explore how different BTK inhibitors compare when it comes to cardiovascular risk and what that means for real-world management. Through expert guidance, you’ll learn how to personalize treatment plans that reflect the latest long-term data and updated guidelines. Practical strategies for preventing, mitigating, and managing cardiovascular complications are covered in depth. You’ll also gain insight into patient perspectives and how interdisciplinary care can enhance outcomes.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Differentiate between the clinical profiles of various BTK inhibitors used in CLL treatment, including long-term data
- Identify and compare the CV risk profiles associated with different BTK inhibitors in CLL therapy
- Develop comprehensive management plans to prevent, mitigate, and manage CV complications in patients with CLL treated with BTK inhibitors, while incorporating recent clinical data and updated guidelines
- Incorporate patient perspectives and multidisciplinary approaches into treatment decisions and long-term management of patients with CLL
Faculty
Stephanie Feldman, MD, FACC
Assistant Professor of Medicine
Weill Cornell Medicine/New York Presbyterian
New York, NY
Daniel Lenihan, MD, FACC
Founder and Board Member, IC-OS
Director, Cardio-Oncology Center of Excellence
Cape Cardiology
Cape Girardeau, MO
Emily Tomasulo, DO, FACP
Assistant Professor of Medicine
University of Pennsylvania
Philadelphia, PA
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The France Foundation and the International Cardio-Oncology Society. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team..
Credit Designation
Physician Credit Designation
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The France Foundation designates this activity for 1.0 contact hour.
Physician Associates
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 8/28/26. PAs should only claim credit commensurate with the extent of their participation.
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Conflict of Interest
Stephanie Feldman, MD, FAAC
- No relevant financial disclosures
Daniel Lenihan, MD, FACC
- Non-CE Consulting: Myocardial Solutions, Intella, AstraZeneca, BMS
Emily Tomasulo, DO, FACP
- Non-CE Consulting: AstraZeneca, Abbvie, Genentech, Sanofi, BMS
- Non-CE Speakers Bureau: AstraZeneca, Abbvie, Genmab, Genentech, BMS
- Research Funding: AstraZeneca
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit, participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
TFF and IC-OS require that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact The France Foundation at 860-434-1650 or [email protected].